Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
